Cancer Vaccines
BioSante Pharmaceuticals Provides Corporate Update
Published in Women's Health Weekly, February 16th, 2012
2012 FEB 16 -- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced a corporate update. Corporate development: In light of the recently announced top-line results from BioSante's two pivotal Phase III LibiGel® (testosterone gel) efficacy trials, BioSante is evaluating its corporate strategy. BioSante continues to investigate alternative strategies to utilize the continuing LibiGel cardiovascular event and breast cancer safety study, and also has begun to explore new product development projects through in-licensing and mergers and acquisitions. In addition, a full review of the GVAX cancer vaccine portfolio is underway.
"We are committed to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
4-week vaccination regimen knocks out early breast cancer tumors, Penn researchers report - Breast Cancer
Children's Hospital Details Research in Breast Cancer - Breast Cancer
Data on Breast Cancer Described by Researchers at Mercy Medical Center - Osteoporosis
Data on Osteoporosis Described by Researchers at University of Toronto - Blood Pressure
Findings from Medical University Broaden Understanding of Blood Pressure - Menopause
Findings from University of California Provide New Insights into Menopause - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
